Association of serum leptin with angiographically proven cardiovascular disease and with components of the metabolic syndrome: a cross-sectional study in East Azerbaijan
Conclusion
Our findings demonstrate that serum leptin levels are associated with components of the MetS and with CVD. Serum leptin may be a useful biomarker for CVD. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - February 18, 2021 Category: Cardiology Tags: Original Articles Source Type: research
Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycaemia in men with type 2 diabetes mellitus: a prospective cohort study
Conclusion
A higher number of CAG repeats at the AR gene associates with higher future HbA1c. There was a ‘u’ shaped relation between CAG repeat number and mortality rate. Determination of CAG repeat number may become part of assessment of androgen status/its consequences for men with T2DM. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - February 18, 2021 Category: Cardiology Tags: Original Articles Source Type: research
Visceral fat reduction and increase of intracellular fluid in weight loss participants on antihypertension medication
Conclusion
A nonpharmacologic, nonsurgical VLCD-based weight loss and metabolic health program is capable of producing clinically meaningful improvements in body composition and physiological endpoints, including those linked to hypertension, cardiovascular disease and inflammation, and is as equally effective for adults taking prescription antihypertensives as it is for those participants who are not. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - February 18, 2021 Category: Cardiology Tags: Original Articles Source Type: research
Coronary microvascular disease: current concepts of pathophysiology, diagnosis and management
Coronary microvascular disease (CMD) is present in 30% of patients with angina and is associated with increased morbidity and mortality. We now have an improved understanding of the pathophysiology of CMD and the invasive and noninvasive tests that can be used to make the diagnosis. Recent studies have shown that management of CMD guided by physiological testing yields better results than empirical treatment. Despite major advances in diagnosing and stratifying this condition, therapeutic strategies remain limited and poorly defined. This review article discusses recent advances in understanding the pathophysiology of CMD,...
Source: Cardiovascular Endocrinology - February 18, 2021 Category: Cardiology Tags: Reviews Source Type: research
The epidemiological status, environmental and genetic factors in the etiology of Keshan disease
Keshan disease (KD) is an endemic cardiomyopathy with myocardial lesions for which the precise etiology has not been determined. It was named after the location where it was first identified: Keshan County in China. KD is mainly distributed in a selenium-deficient zone from northeast to southwest China. In recent years, the incidence and prevalence of KD have significantly decreased. Meanwhile, more knowledge was accumulated about the etiology of KD and recent data indicated that genetic factor was involved. In this review, we will first update an overview of the epidemiological status and the environmental and genetic fac...
Source: Cardiovascular Endocrinology - February 18, 2021 Category: Cardiology Tags: Reviews Source Type: research
Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond
Sodium-glucose co-transporter 2 Inhibitors (SGLT2i) were initially developed as therapeutic options for patients with type 2 diabetes mellitus (T2DM). Recently, randomized clinical trials have investigated their effects in cardiorenal protection through major adverse cardiovascular event reduction and reductions in diabetic nephropathy. While multiple mechanisms are proposed for this protection, microvascular protection is the primary component of their efficacy. While not primarily emphasized in clinical trials, evidence in other studies suggests that SGLT2i may confer retinoprotective effects via some of the same mechani...
Source: Cardiovascular Endocrinology - February 18, 2021 Category: Cardiology Tags: Reviews Source Type: research
COVID-19 pandemic: a glimpse into newly diagnosed hypertensive patients
No abstract available (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - February 18, 2021 Category: Cardiology Tags: Viewpoint Source Type: research
A 78-year-old male with inferior ST-segment elevation on electrocardiogram, diabetic ketoacidosis and acute pancreatitis
A 78-year-old male presented with shortness of breath, metabolic acidosis, severe hyperglycaemia and ketonemia. Inferior ST-elevation was present on 12-lead ECG with raised troponin I, but coronary arteries were normal on emergency cardiac catheterization. Despite no previous history of diabetes mellitus and normal HbA1c levels 7 months prior, diabetic ketoacidosis (DKA) was diagnosed, complicated by subsequent shock. The underlying cause was acute pancreatic disease, supported by elevated pancreatic enzyme levels and a history of chronic heavy alcohol use. There are no previous reports, to our knowledge, of patients with ...
Source: Cardiovascular Endocrinology - November 20, 2020 Category: Cardiology Tags: Case Report Source Type: research
Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data
With sustained growth of diabetes numbers, sustained patient engagement is essential. Using nationally available data, we have shown that the higher mortality associated with a diagnosis of T1DM/T2DM could produces loss of 6.4 million future life years in the current UK population. In the model, the ‘average’ person with T1DM (age 42.8 years) has a life expectancy from now of 32.6 years, compared to 40.2 years in the equivalent age non diabetes mellitus population, corresponding to lost life years (LLYs) of 7.6 years/average person. The ‘average’ person with T2DM (age 65.4 years) has a life expectancy fro...
Source: Cardiovascular Endocrinology - November 20, 2020 Category: Cardiology Tags: Short Report Source Type: research
Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus
Conclusions
In a large cohort of patients with T2DM elevated HbA1c levels at baseline did not consistently predict increased risk of all-cause and cardiovascular mortality across the different BMI categories. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - November 20, 2020 Category: Cardiology Tags: Original Articles Source Type: research
The FreeStyle Libre flash glucose monitoring system: how it has improved glycaemic control for people with type 1 diabetes in Eastern Cheshire, UK
Conclusion
Flash glucose monitoring has great potential for the management of type 1 diabetes in the adult population and improving metabolic control/quality of life for people across the world. The technology provides significantly more data than the intermittent results obtained by traditional subcutaneous blood glucose monitoring, which may not capture intervals of extreme variability or nocturnal events. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - November 20, 2020 Category: Cardiology Tags: Original Articles Source Type: research
Revisiting the pathogenic role of insulin resistance in Duchenne muscular dystrophy cardiomyopathy subphenotypes
Introduction
Duchenne muscular dystrophy (DMD) is known to impact the subepicardial layer of the myocardium through chronic inflammation. Recent animal studies have shown predominant subendocardial involvement in rats with DMD. The primary outcome parameter was to determine by cardiovascular MRI (CMR) if two differential patterns of myocardial involvements exist in DMD; the secondary outcome parameters were to correlate the observed pattern with metabolic markers such as insulin resistance measures.
Methods
Forty patients with DMD were screened using CMR to determine which of them had predominantly subendocardia...
Source: Cardiovascular Endocrinology - November 20, 2020 Category: Cardiology Tags: Original Articles Source Type: research
Type 2 diabetes prevalence in Pakistan: what is driving this? Clues from subgroup analysis of normal weight individuals in diabetes prevalence survey of Pakistan
Background
Type 2 diabetes mellitus (T2DM) is a global health tissue. We determined factors relating to the likelihood of developing T2DM in normal BMI individuals.
Methodology
This was a cross-sectional community-based representative survey, of people aged ≥20 years in Pakistan, using HBA1c as the screening tool. The prevalence of T2DM/prediabetes in people having normal BMI together with associated risk factors was estimated.
Results
Of 6824 normal BMI individuals, there was still a high prevalence of T2DM 14.92% and in underweight at 10.14% (overall prevalence 16.96%). Corresponding rates for prediab...
Source: Cardiovascular Endocrinology - November 20, 2020 Category: Cardiology Tags: Original Articles Source Type: research
Clinical presentation of paroxysmal supraventricular tachycardia: evaluation of usual and unusual symptoms
Conclusions
Paroxysmal supraventricular tachycardia might manifest itself as gastrointestinal, neurological, psychosomatic symptoms, and unusual complaints in association with or without main symptoms, including palpitation, chest pain, syncope, and dyspnea. Symptoms after tachycardia or index event should be questioned systematically. (Source: Cardiovascular Endocrinology)
Source: Cardiovascular Endocrinology - November 20, 2020 Category: Cardiology Tags: Original Articles Source Type: research
The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model
PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequate response. PCSK9 inhibitors, in addition to modulating lipid metabolism, improve mortality outcomes in cardiovascular disease. These benefits are markedly pronounced in patients with type 2 diabetes mellitus. However, these benefits do not come without associated risk. Multiple trials, studies, and case reports have attempted to explain observed outcomes with PCSK9 expression ...
Source: Cardiovascular Endocrinology - November 20, 2020 Category: Cardiology Tags: Review Articles Source Type: research
